TRADEMARK ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Avedro, Inc.	FORMERLY Thermal Vision, Inc.	02/08/2012	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Venture Lending & Leasing VI, Inc.
Street Address:	104 La Mesa Drive, Suite 102
City:	Portola Valley
State/Country:	CALIFORNIA
Postal Code:	94028
Entity Type:	CORPORATION: MARYLAND

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Registration Number:	3706910	KERAFLEX
Registration Number:	3700320	AVEDRO
Registration Number:	3883816	VEDERA
Serial Number:	77442851	AVEDRO
Serial Number:	77442853	KERAFLEX
Serial Number:	77943321	BIOINSULATOR
Serial Number:	85152906	LASIK XTRA
Serial Number:	85349759	PARACEL
Serial Number:	85349744	KXL
Serial Number:	85349763	VIBEX
Serial Number:	85349766	VIBEX XTRA

OP $290.00 3706910

CORRESPONDENCE DATA

Fax Number: (415)777-4961
Phone: 415 981 1400

Email:	gkiviat@grmslaw.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.	
Correspondent Name:	Jeffrey T. Klugman
Address Line 1:	Four Embarcadero Center, Suite 4000
Address Line 4:	San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	47558/00131
NAME OF SUBMITTER:	Jeffrey T. Klugman
Signature:	/Jeffrey T. Klugman/
Date:	02/13/2012

Total Attachments: 20
source=Avedro, Inc. - 6-0131#page1.tif
source=Avedro, Inc. - 6-0131#page2.tif
source=Avedro, Inc. - 6-0131#page3.tif
source=Avedro, Inc. - 6-0131#page4.tif
source=Avedro, Inc. - 6-0131#page5.tif
source=Avedro, Inc. - 6-0131#page6.tif
source=Avedro, Inc. - 6-0131#page7.tif
source=Avedro, Inc. - 6-0131#page8.tif
source=Avedro, Inc. - 6-0131#page9.tif
source=Avedro, Inc. - 6-0131#page10.tif
source=Avedro, Inc. - 6-0131#page11.tif
source=Avedro, Inc. - 6-0131#page12.tif
source=Avedro, Inc. - 6-0131#page13.tif
source=Avedro, Inc. - 6-0131#page14.tif
source=Avedro, Inc. - 6-0131#page15.tif
source=Avedro, Inc. - 6-0131#page16.tif
source=Avedro, Inc. - 6-0131#page17.tif
source=Avedro, Inc. - 6-0131#page18.tif
source=Avedro, Inc. - 6-0131#page19.tif
source=Avedro, Inc. - 6-0131#page20.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of February 8, 2012, by and between AVEDRO, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING VI, INC., a Maryland corporation ("Secured Party").

RECITALS

A. Pursuant to that certain Loan and Security Agreement of even date herewith between Grantor, as borrower, and Secured Party, as lender (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest and mortgage to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of

the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor has rights (as defined in the UCC) in the Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for Permitted Liens and except for transfers otherwise permitted under the Loan Agreement;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(d) **Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal quarter, a report signed by Grantor, in form reasonably acceptable to Secured Party, listing (i) any applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks, (ii) the status of any outstanding applications or registrations and (iii) any material change in the composition of the Collateral;**

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Secured Party in writing of material infringements detected and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public unless Grantor deems it to be in the best interest of Grantor's business;

(f) Grantor shall apply for registration (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except, in each case, with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral. Grantor shall give Secured Party notice of all such applications or registrations; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts, except for provisions in such material contracts as are referenced in the last paragraph of Section 1 of this Agreement.

3. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, this Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without

the signature of Grantor where permitted by law, and (iii) subject to the terms of the Supplement to the Loan Agreement, after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor breaches any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

[Signature Pages Follow]

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

GRANTOR:

ORIGINAL

AVEDRO, INC.

Address of Grantor:

230 Third Avenue
Waltham, MA 02451
Attn: Chief Executive Officer

By: _____

Name: David Muller

Its: CEO

SECURED PARTY:

VENTURE LENDING & LEASING VI, INC.

Address of Secured Party:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer

By: _____

Name: _____

Its: _____

47558/0131
JTK/405592.1

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

GRANTOR:

Address of Grantor:

AVEDRO, INC.

230 Third Avenue
Waltham, MA 02451
Attn: Chief Executive Officer

By: _____

Name: _____

Its: _____

SECURED PARTY:

Address of Secured Party:

VENTURE LENDING & LEASING VI, INC.

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer

By: _____

Name: Maurice Werdegar

Its: President and CEO

ORIGINAL

47558/0131
JTK/405592.1

EXHIBIT A

Copyrights

Description	Registration Number	Registration Date
None.		

EXHIBIT B

Patents

Pat. App. No. (Pub. No.)	Filing Date	APPLICATION TITLE Description	Status
US 60/929,946 provisional	*7/19/2007*	***EYE THERAPY SYSTEM*** *Application of coolant to the eye during thermokeratoplasty*	*Expired provisional application*
US 11/898,189 (2009-0024117)	9/10/2007	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty	Response to final Office Action with RCE filed on 11/10/2010.
US 12/208,963 (2009-0069798)	9/11/2008	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty; Application of thin electrode for thermokeratoplasty; Delivery of high power during thermokeratoplasty	Response to Restriction/Election Requirement filed 9/17/2011, electing claims 1-19 (device claims); Non-final Office Action mailed 12/5/2011 – Response due 3/5/2012
PCT/US08/70640 (WO 2009/012490)	*7/21/2008*	***EYE THERAPY SYSTEM*** *Application of coolant to the eye during thermokeratoplasty*	*Expired PCT application*
PCT/US08/76023 (WO 2010/039117)	*9/11/2008*	***EYE THERAPY SYSTEM*** *Application of coolant to the eye during thermokeratoplasty; Application of thin electrode for thermokeratoplasty; Delivery of high power during thermokeratoplasty*	*Expired PCT application*
JP 2010-517202	1/19/2010	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty	First Office Action pending
EP 08796370.8	1/28/2010	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty	Response to Written Opinion filed by 12/2/2011.
KR 10-2010-7003770	2/19/2010	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty	First Office Action pending
CN 200880105990.8	*3/8/2010*	***EYE THERAPY SYSTEM*** *Application of coolant to the eye during thermokeratoplasty*	*Application abandoned.*
EP 08822043.9	4/8/2011	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty	Response to EP Communication filed by 11/23/2011.
JP 2011-526840	3/11/2011	**EYE THERAPY SYSTEM** Application of coolant to the eye during thermokeratoplasty	First Office Action pending

US 12/018,450 (2009-0187178)	1/23/2008	**SYSTEM AND METHOD FOR POSITIONING AN EYE THERAPY DEVICE** Positioning of an applicator for thermokeratoplasty to deliver energy to targeted areas	Response to first Office Action filed on 11/16/2011; Final Office Action mailed 11/28/2011 – Response due 2/28/2011 – Case to be interviewed
PCT/US09/31716 (WO 2009/094468)	*1/22/2009*	***SYSTEM AND METHOD FOR POSITIONING AN EYE THERAPY DEVICE*** *Positioning of an applicator for thermokeratoplasty to deliver energy to targeted areas*	*Expired PCT application*
EP 08799473.7	8/18/2010	**SYSTEM AND METHOD FOR POSITIONING AN EYE THERAPY DEVICE** Positioning of an applicator for thermokeratoplasty to deliver energy to targeted areas	First Office Action pending
JP 2010-544421	7/22/2010	**SYSTEM AND METHOD FOR POSITIONING AN EYE THERAPY DEVICE** Positioning of an applicator for thermokeratoplasty to deliver energy to targeted areas	First Office Action pending
US 12/018,457 (2009-0187184)	1/23/2008	**SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE** Accurate and consistent application of an applicator during thermokeratoplasty	Response to first Office Action filed 11/17/2011; Final Office Action mailed 1/11/2012 – Response due 4/11/2012 – Case to be interviewed
US 12/209,123 (2009-0209954)	9/11/2008	**SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE** Accurate and consistent application of an applicator during thermokeratoplasty	Response to first Office Action filed 1/5/2012
PCT/US08/76062 (WO 2009/094049)	*9/11/2008*	***SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE*** *Accurate and consistent application of an applicator during thermokeratoplasty*	*Expired PCT application*
EP 08799473.7	8/17/2010	**SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE** Accurate and consistent application of an applicator during thermokeratoplasty	Response to Written Opinion filed by 12/20/2011
PCT/US09/31718 (WO 2009/094470)	*1/22/2009*	***SYSTEM AND METHOD FOR POSITIONING AN EYE THERAPY DEVICE*** *Accurate and consistent application of an applicator during thermokeratoplasty*	*Expired PCT application*
EP 09704233.7	8/17/2010	**SYSTEM AND METHOD FOR POSITIONING AN EYE THERAPY DEVICE** Accurate and consistent application of an	Response to Written Opinion filed 08/11/2011

		applicator during thermokeratoplasty	
US 12/018,473 (2009-0187173)	1/23/2008	**SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE** Application of additional reshaping forces to the cornea during thermokeratoplasty	Response to final Office Action with RCE filed on 1/18/2011
PCT/US09/31715 (WO 2009/094467)	*1/22/2009*	***SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE*** *Application Of additional reshaping forces to the cornea during thermokeratoplasty*	*Expired PCT application*
EP 09703726.1	8/23/2010	**SYSTEM AND METHOD FOR RESHAPING AN EYE FEATURE** Application Of additional reshaping forces to the cornea during thermokeratoplasty	Response to Written Opinion filed 08/11/2011
US 12/113,672 (2009-0275936)	5/1/2008	**SYSTEM AND METHOD FOR APPLYING THERAPY TO AN EYE USING ENERGY CONDUCTION** Application of energy to an eye during thermokeratoplasty for the treatment of astigmatism	First Office Action pending
PCT/US09/42204 (WO 2009/134953)	4/30/2009	**SYSTEM AND METHOD FOR APPLYING THERAPY TO AN EYE USING ENERGY CONDUCTION** Application of energy to an eye during thermokeratoplasty for the treatment of astigmatism	*Expired PCT application; no national phase filings*
US 60/992,486 provisional	*12/5/2007*	***METHOD FOR MAINTAINING CORNEAL SHAPE AFTER THERMOKERATOPLASTY*** *Application of a shape retention (cross-linking) substance to an eye to preserve the results of thermokeratoplasty; Devices for patterned application of UV light; Use of heat sensitive liposomes for delivering cross-linking agent; Use of FACIT collagens and LRR proteoglycans*	*Expired provisional application*
US 12/315,829 (2009-0149842)	12/5/2008	**EYE THERAPY SYSTEM** Application of a shape retention (cross-linking) substance to an eye to preserve the results of thermokeratoplasty; Devices for patterned application of UV light; Use of heat sensitive liposomes for delivering cross-linking agent; Use of FACIT collagens and LRR	First Office Action pending

		proteoglycans	
PCT/US08/013426 (WO 2009/073213)	*12/5/2008*	***EYE THERAPY SYSTEM*** Application of a shape retention (cross-linking) substance to an eye to preserve the results of thermokeratoplasty; Devices for patterned application of UV light; Use of heat sensitive liposomes for delivering cross-linking agent; Use of FACIT collagens and LRR proteoglycans	*Expired PCT application*
JP 2010-536938	6/4/2010	**EYE THERAPY SYSTEM** Application of a shape retention (cross-linking) substance to an eye to preserve the results of thermokeratoplasty; Devices for patterned application of UV light; Use of heat sensitive liposomes for delivering cross-linking agent; Use of FACIT collagens and LRR proteoglycans	First Office Action pending
EP 08855817.6	7/1/2010	Application of a shape retention (cross-linking) substance to an eye to preserve the results of thermokeratoplasty; Devices for patterned application of UV light; Use of heat sensitive liposomes for delivering cross-linking agent; Use of FACIT collagens and LRR proteoglycans	Response to Written Opinion filed by 12/20/2011
US 61/098,489 provisional	*9/19/2008*	***EYE THERAPY SYSTEM*** *Multi-step operation of a device configured to apply thermokeratoplasty; initiation of cross-linking for the application of thermokeratoplasty*	*Expired provisional application*
US 12/562,625 (2010-0076423)	9/18/2009	**EYE THERAPY SYSTEM** *Multi-step operation of a device configured to apply thermokeratoplasty.*	First Office Action pending
PCT/US09/57481 (WO 2010/033804)	*9/18/2009*	***EYE THERAPY SYSTEM*** *Multi-step operation of a device configured to apply thermokeratoplasty*	*Expired PCT application*
EP 09815266.3	4/19/2011	**EYE THERAPY SYSTEM** Multi-step operation of a device configured to apply thermokeratoplasty	Amended claims filed by 12/3/2011
JP 2011-527996	3/18/2011	**EYE THERAPY SYSTEM** Multi-step operation of a device configured to apply thermokeratoplasty	First Office Action pending
US 61/101,496 provisional	*9/30/2008*	***EYE THERAPY SYSTEM*** *Initiation of cross-linking in corneal tissue with AGE forming agent*	*Expired provisional application*
US 12/570,959 (2010-0094197)	9/30/2009	**EYE THERAPY SYSTEM** Initiation of cross-linking in corneal	Non-final Office Action mailed 1/25/2012, includes allowed claims

		tissue with AGE forming agent	
PCT/US2009/59061 (WO 2010/039854)	9/30/2009	**EYE THERAPY SYSTEM** Initiation of cross-linking in corneal tissue with AGE forming agent	*Expired PCT application; no national phase filings*
US 61/101,503 provisional	*9/30/2008*	***EYE THERAPY SYSTEM*** *Multi-step operation of a device configured to apply thermokeratoplasty*	*Expired provisional application*
US 61/101,509 provisional	*9/30/2008*	***EYE THERAPY SYSTEM*** *Patterned initiation of cross-linking during thermokeratoplasty*	*Expired provisional application*
US 61/101,820 provisional	*10/1/2008*	***EYE THERAPY SYSTEM*** *Localized application of energy during thermokeratoplasty for the treatment of astigmatism;* *Application of a patterned dielectric during thermokeratoplasty for the treatment of astigmatism*	*Expired provisional application*
US 12/572,019 (2010-0094280)	10/1/2009	**EYE THERAPY SYSTEM** Localized application of energy during thermokeratoplasty for the treatment of astigmatism; Application of a patterned dielectric during thermokeratoplasty for the treatment of astigmatism	First Office Action pending
PCT/US09/59260 (WO 2010/039979)	*10/1/2009*	***EYE THERAPY SYSTEM*** *Localized application of energy during thermokeratoplasty for the treatment of astigmatism;* *Application of a patterned dielectric during thermokeratoplasty for the treatment of astigmatism*	*Expired PCT application*
EP 09818518.4	4/21/2011	**EYE THERAPY SYSTEM** Localized application of energy during thermokeratoplasty for the treatment of astigmatism; Application of a patterned dielectric during thermokeratoplasty for the treatment of astigmatism	First Office Action pending
JP 2011-530246	4/1/2011	**EYE THERAPY SYSTEM** Localized application of energy during thermokeratoplasty for the treatment of astigmatism; Application of a patterned dielectric during thermokeratoplasty for the treatment of astigmatism	First Office Action pending
US 61/113,395 provisional	*11/11/2008*	***EYE THERAPY SYSTEM*** *Tissue contact and cooling sensing according to power measurements*	*Expired provisional application*
US 12/617,554 (2010-0185192)	11/12/2009	**EYE THERAPY SYSTEM** Tissue contact and cooling sensing	Petition for Patent Prosecution Highway granted 9/18/2011;

		according to power measurements	Response to Restriction/Election Requirement filed 1/23/2012
PCT/US09/64189 (WO 2010/056848)	*11/12/2009*	***EYE THERAPY SYSTEM*** *Tissue contact and cooling sensing according to power measurements*	*Expired PCT application*
EP 09826739.6	6/6/2011	**EYE THERAPY SYSTEM** Tissue contact and cooling sensing according to power measurements	First Office Action pending
JP 2011-536463	5/11/2011	**EYE THERAPY SYSTEM** Tissue contact and cooling sensing according to power measurements	First Office Action pending
US 61/166,002 Provisional	*4/2/2009*	***EYE THERAPY SYSTEM*** *Accurate and consistent application of a segmented applicator for thermokeratoplasty*	*Expired provisional application*
12/753,523 (2010-0256705)	4/2/2010	**EYE THERAPY SYSTEM** Accurate and consistent application of a segmented applicator for thermokeratoplasty	First Office Action pending
PCT/US10/29806 (WO 2010/115121)	4/2/2010	**EYE THERAPY SYSTEM** Accurate and consistent application of a segmented applicator for thermokeratoplasty	No national phase filings
US 61/166,009 Provisional	*4/2/2009*	***EYE THERAPY SYSTEM*** *Multi-step operation of an applicator having a series of concentric differently dimensioned (inner) electrodes to apply thermokeratoplasty*	*Expired provisional application*
US 12/753,465 (2010-0256626)	4/2/2010	**EYE THERAPY SYSTEM** Multi-step operation of an applicator having a series of concentric differently dimensioned (inner) electrodes to apply thermokeratoplasty	First Office Action pending
PCT/US10/29812 (WO 2010/115126)	*4/2/2010*	***EYE THERAPY SYSTEM*** *Multi-step operation of an applicator having a series of concentric differently dimensioned (inner) electrodes to apply thermokeratoplasty*	*Expired PCT application*
		EYE THERAPY SYSTEM Multi-step operation of an applicator having a series of concentric differently dimensioned (inner) electrodes to apply thermokeratoplasty	
		EYE THERAPY SYSTEM Multi-step operation of an applicator having a series of concentric differently dimensioned (inner) electrodes to apply thermokeratoplasty	
US 61/165,998 Provisional	*4/2/2009*	***EYE THERAPY SYSTEM*** *Accurate and consistent application of*	*Expired provisional application*

		an applicator including an integral spring for thermokeratoplasty	
US 12/753,662 (2010-0280509)	4/2/2010	**EYE THERAPY SYSTEM** Accurate and consistent application of an applicator including an integral spring for thermokeratoplasty	First Office Action pending
PCT/US10/29791 (WO 2010/115109)	4/2/2010	**EYE THERAPY SYSTEM** Accurate and consistent application of an applicator including an integral spring for thermokeratoplasty	No national phase filings
US 61/253,736 Provisional	*10/21/2009*	***EYE THERAPY SYSTEM*** *O2 supersaturation of Riboflavin; Rose Bengal as a cross-linking agent*	*Expired provisional application*
US 12/909,228 (2011-0118654)	10/21/2010	**EYE THERAPY SYSTEM** O2 supersaturation of Riboflavin; Rose Bengal as a cross-linking agent	First Office Action pending
PCT/US10/53551	10/21/2010	**EYE THERAPY SYSTEM** O2 supersaturation of Riboflavin; Rose Bengal as a cross-linking agent	National phase filing due 4/21/2012
US 61/256,714 provisional	*10/30/2009*	***SYSTEM AND METHOD FOR STABILIZING CORNEAL TISSUE AFTER TREATMENT*** *Inhibiting wound healing*	*Expired provisional application*
US 12/915,646 (2011-0118716)	10/29/2010	**SYSTEM AND METHOD FOR STABILIZING CORNEAL TISSUE AFTER TREATMENT** Inhibiting wound healing	Petition for Patent Prosecution Highway granted 9/18/2011; Non-final Office Action mailed 11/29/2011, including allowed claims – Response due 2/28/2012
PCT/US10/54673	10/29/2010	**SYSTEM AND METHOD FOR STABILIZING CORNEAL TISSUE AFTER TREATMENT** Inhibiting wound healing	National phase filing due 4/29/2012
US 61/315,840 provisional	*03/19/2010*	***EYE THERAPY*** *Cross-linking in combination with LASIK treatment*	*Expired provisional application*
US 61/319,111 provisional	*03/30/2010*	***EYE THERAPY*** *Initiating cross-linking agent with laser scanning technology (DLP)*	*Expired provisional application*
US 61/326,527 provisional	*04/21/2010*	***EYE THERAPY*** *Iterative variations of concentration, time, power to initiate 3D regions of cross-linking*	*Expired provisional application*
US 61/323,388 provisional	*04/13/2010*	***EYE THERAPY*** *Cross-linking agent penetration by: ultrasound, microspheres, ionophoresis, neutral compound*	*Expired provisional application*

US 61/328,138 provisional	*04/26/2010*	***EYE THERAPY*** *LASIK with cross-linking while flap is open after calculating time for penetration of cross-linking agent and corneal thickness*	*Expired provisional application*
US 61/345,873 provisional	*05/18/2010*	***EYE THERAPY*** *Promoting delivery of cross-linking by applying energy in a pattern to corneal tissue to increase porosity*	*Expired provisional application*
US 61/377,024 provisional	*08/25/2010*	***EYE THERAPY*** *Application of cross-linking treatment agent outside of treatment zone after thermokeratoplasty (w/ mask); time staged cross-linking by examining structure each time*	*Expired provisional application*
US 61/378,281 provisional	*08/25/2010*	***EYE THERAPY*** *Application of reverse osmotic fluid to control concentration of cross-linking agent applied to the cornea*	*Expired provisional application*
US 61/388,963 provisional	*10/1/2010*	***EYE THERAPY*** *Birefringence, interferometry for real time monitoring of cross-linking*	*Non-provisional filed*
US 61/409,103 provisional	*11/1/2010*	***EYE THERAPY*** *Dynamic interferometry system for monitoring of cross-linking*	*Non-provisional filed*
US 61/423,375 provisional	*11/15/2010*	***EYE THERAPY*** *Accelerated cross-linking; Increase in bandwidth of excitation source; eye tracking and DLP; 3D regions of cross-linking*	*Non-provisional filed*
US 61/431,367 provisional	1/10/2011	**EYE THERAPY** Storage vessel and delivery system for cross-linking agent	Non-provisional application not filed
US 13/051,699 (2011-0237999)	3/18/2011	**SYSTEMS AND METHODS FOR APPLYING AND MONITORING EYE THERAPY** Cross-linking in combination with LASIK treatment; Initiating cross-linking agent with laser scanning technology (DLP); Iterative variations of concentration, time, power to initiate 3D regions of cross-linking; LASIK with cross-linking while flap is open after calculating time for penetration of cross-linking agent and corneal thickness; Application of cross-linking treatment agent outside of treatment zone after thermokeratoplasty (w/ mask);	Claims priority to 060PL01, 061PL01, 062PL01, 064PL01, 068PL01, 072PL01, 073PL01, 076PL01

		time staged cross-linking by examining structure each time; Birefringence, interferometry for real time monitoring of cross-linking; Dynamic interferometry system for monitoring of cross-linking; Accelerated cross-linking; Increase in bandwidth of excitation source; eye tracking and DLP; 3D regions of cross-linking	
PCT/US11/29033	3/18/2011	**SYSTEMS AND METHODS FOR APPLYING AND MONITORING EYE THERAPY** Cross-linking in combination with LASIK treatment; Initiating cross-linking agent with laser scanning technology (DLP); Iterative variations of concentration, time, power to initiate 3D regions of cross-linking; LASIK with cross-linking while flap is open after calculating time for penetration of cross-linking agent and corneal thickness; Application of cross-linking treatment agent outside of treatment zone after thermokeratoplasty (w/ mask); time staged cross-linking by examining structure each time; Birefringence, interferometry for real time monitoring of cross-linking; Dynamic interferometry system for monitoring of cross-linking; Accelerated cross-linking; Increase in bandwidth of excitation source; eye tracking and DLP; 3D regions of cross-linking	Claims priority to 060PL01, 061PL01, 062PL01, 064PL01, 068PL01, 072PL01, 073PL01, 076PL01
US 13/086,019	4/13/2011	**SYSTEMS AND METHODS FOR ACTIVATING CROSS-LINKING IN AN EYE** Cross-linking agent penetration by: ultrasound, microspheres, ionophoresis, neutral compound; Iterative variations of concentration, time, power to initiate 3D regions of cross-linking; Promoting delivery of cross-linking by applying energy in a pattern to corneal tissue to increase porosity; Application of reverse osmotic fluid	Claims priority to 062PL01, 063PL01, 065PL01, 069PL01

		to control concentration of cross-linking agent applied to the cornea	
PCT/US11/32234	4/13/2011	**SYSTEMS AND METHODS FOR ACTIVATING CROSS-LINKING IN AN EYE** Cross-linking agent penetration by: ultrasound, microspheres, ionophoresis, neutral compound; Iterative variations of concentration, time, power to initiate 3D regions of cross-linking; Promoting delivery of cross-linking by applying energy in a pattern to corneal tissue to increase porosity; Application of reverse osmotic fluid to control concentration of cross-linking agent applied to the cornea	Claims priority to 062PL01, 063PL01, 065PL01, 069PL01
US 61/477,505 provisional	4/20/2011	**SYSTEMS AND METHODS FOR INITIATING EYE THERAPY WITH DISTANCE INVARIANCE** Use of lasers as light source to initiate cross-linking	Non-provisional application to be filed by 4/20/2012;
US 61/484,572 provisional	5/10/2011	**STERILIZING APPLICATION OF RIBOFLAVIN AND ULTRAVIOLET LIGHT** Application of Riboflavin and UV light *in vivo* to sterilize a field for an invasive procedure	Non-provisional application to be filed by 5/10/2012
US 61/487,404 provisional	5/18/2011	**CONTROL OF RIBOFLAVIN MEDIATED UV CROSS-LINKING** Quenching of residual Riboflavin that remains in the corneal tissue after the desired cross-linking activity has been achieved	Non-provisional application to be filed by 5/18/2012
US 61/492,553 provisional	6/2/2011	**SYSTEMS AND METHODS FOR MONITORING TIME BASED PHOTO ACTIVE AGENT DELIVERY OR PHOTO ACTIVE MARKER PRESENCE** Monitoring time based photo active agent delivery or photo active marker presence, *e.g.*, with a Scheimpflug optical system configured to take cross sectional images of the eye before and during instillation of a cross-linking agent to monitor the tissue uptake and drug concentration as a function of depth within the tissue	Non-provisional application to be filed by 6/2/2012
US 61/492,499 provisional	6/2/2011	**SYSTEMS AND METHOD FOR RESHAPING AN EYE FEATURE**	Non-provisional application to be filed by 6/2/2012

		Cutting a dissection plane in the cornea to at least partially disassociate or separate the anterior corneal tissue from the posterior corneal tissue to provide one or more areas of stress relief to achieve desired reshaping	
US 61/489,554 provisional	5/24/2011	**SYSTEMS AND METHODS FOR APPLYING EYE TREATMENT WITH A CROSS-LINKING AGENT** Correction of post-procedural refractive errors by the application of a cross-linking agent	Non-provisional application to be filed by 5/24/2012
US 61/521,261 provisional	8/8/2011	**SYSTEMS AND METHODS FOR APPLYING AND MONITORING EYE THERAPY** Correction for both myopia and astigmatism using cross-linking therapy that provides asymmetric corneal strengthening. Dosage adjusted based on the biomechanical properties of the eye. Doses beyond 5 J/cm2 have been found effective for activating cross-linking in corneal tissue.	Non-provisional application to be filed by 8/8/2012;
US 61/542,269 provisional	10/2/2011	**SYSTEMS AND METHODS FOR APPLYING AND MONITORING EYE THERAPY** Biomechanical properties of eye tissue are characterized by perturbing the eye tissue with the introduction of ultrasonic shear waves inside the corneal tissue and simultaneously observing the effect of the perturbation using an optical coherence tomography system.	Non-provisional application to be filed by 10/2/2012
US 61/550,576 provisional	10/24/2011	**SYSTEMS AND METHODS FOR APPLYING AND MONITORING EYE THERAPY** Biomechanical properties of eye tissue are characterized by perturbing the eye tissue with a configuration of ultrasonic micro-transducers and simultaneously observing the effect of the perturbation using an optical coherence tomography system.	Non-provisional application to be filed by 10/24/2012
US 61/555,925 provisional	11/4/2011	**SYSTEMS AND METHODS FOR CREATING CONCENTRATION GRADIENTS FOR CROSS-LINKING TREATMENTS OF THE EYE** Systems and methods apply varying concentrations of cross-linking agent to	Non-provisional application to be filed by 11/4/2012

		corneal tissue for cross-linking treatments. In particular, reverse osmotic substances, *e.g.*, hypotonic solutions, gels, *etc.*, are applied to create reverse-osmotic pressure to draw the cross-linking agent out of sections of corneal tissue to effect a customized concentration profile for the cross-linking agent in the corneal tissue.	
61/586,788	1/15/2012	**SYSTEMS AND METHODS FOR DELIVERING CROSS-LINKING AGENT TO CORNEAL TISSUE BY CONTROLLING TEMPERATURE** Systems and methods control the distribution of the cross-linking agent in the corneal tissue by controlling the temperature of the cross-linking agent during application.	Non-provisional application to be filed by 1/15/2013
61/566,976	12/5/2011	**SYSTEMS AND METHODS FOR MONITORING TIME BASED PHOTO ACTIVE AGENT DELIVERY OR PHOTO ACTIVE MARKER PRESENCE** Monitoring time based photo active agent delivery or photo active marker presence with configurations of a Scheimpflug optical system to monitor the tissue uptake and drug concentration as a function of depth within the tissue.	Non-provisional application to be filed by 12/5/2012
61/594,796	2/3/2012	**FLUORESCENCE DOSIMETRY METHOD FOR CORNEAL CROSS-LINKING WITH RIBOFLAVIN** A method for fluorescence dosimetry and corneal cross-linking with riboflavin has been demonstrated. Scheimpflug system imaging combined with a filter was used to determine the riboflavin fluorescence in the cornea before, during and after UVA irradiation. Based on this concept a digital micro-mirror device (DMD) UVA projector and imaging system was assembled and used to measure diffusion coefficients.	Non-provisional application to be filed by 2/3/2013

EXHIBIT C

The Company has filed the following trademark applications in the United States:

Mark	Serial No.	Filing/RegisteredDate	Status	Class
Avedro	77442851	04/08/08	Filed/Allowed	44
Avedro	77977753	10/20/09	Registered	10
Keraflex	77977838	11/03/09	Registered	10
Keraflex	77442853	04/08/08	Filed/Allowed	44
Vedera	77785078	11/30/10	Registered/Issued	10
BioInsulator	77943321	02/24/10	Filed/Allowed	10
Lasik Xtra	85/152906	10/14/10	Filed/Allowed	44
Paracel	85/349,759	06/17/11	Filed/Allowed	5
KXL	85/349,744	06/17/11	Filed/Allowed	44
Vibex	85/349,763	06/17/11	Filed/Suspended*	5
Vibex Xtra	85/349,766	06/17/11	Filed/Suspended*	5

** Pending disposition of earlier filed application*

The Company has filed the following trademark applications outside the United States:

Mark	Jurisdiction	CTM Application Number	Status	Filing/ Registered Date
Avedro	Europe	007298888	Registered	05/14/09
Keraflex	Europe	007298763	Registered	05/14/09
Avedro	China P.R.	7637171	Registered	11/21/10
Avedro	China P.R.	7637172	Registered	12/21/10
Keraflex	China P.R.	7637169	Registered	11/21/10
Keraflex	China P.R.	7637170	Registered	12/21/10
Avedro	Japan	2009-056649	Registered	12/18/09
Keraflex	Japan	2009-056878	Registered	12/11/09
Lasik Xtra	Japan	2011-23437	Filed/Pending	04/04/11
Avedro	South Korea	45-2009-2725	Registered	06/24/10
Keraflex	South Korea	45-2009-2718	Registered	06/24/10